ReviewJournal of nanobiotechnology2023
Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress.
Review in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Reprogramming Glial Cell Metabolism via a tRNA Fragment Preserves Vision in Retinal Neurodegeneration.MedComm · 2026Article
- Mucoadhesive and corneal permeable nano eye drops for improved anti-glaucoma therapy.Journal of nanobiotechnology · 2026Article
- Overview of Intracameral Drug Delivery Systems in Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Global research status in the treatment of glaucoma: a systematic bibliometric analysis.International journal of ophthalmology · 2026Article
- Brinzolamide encapsulated β-cyclodextrin-chondroitin sulfate nanocomplexes anchored chitosan/polycaprolactone nanofibers as an ocular insert for glaucoma treatment.Materials today. Bio · 2025Article
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- Applying nanotechnology to glaucoma therapy: past, present, and future.Nanomedicine (London, England) · 2025Article
- Development of a Liposome Nanoformulation for the Delivery of Lipoic Acid as a Potential Neuroprotective Therapy in Glaucoma.Pharmaceutics · 2025Article
- Advancements and Prospects in Nanorobotic Applications for Ophthalmic Therapy.ACS biomaterials science & engineering · 2025Review
- Fish Fin-Derived Non-Invasive Flexible Bioinspired Contact Lens for Continuous Ophthalmic Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Intravitreal drug injection for glaucoma: mechanisms, clinical efficacy, and future horizons.Frontiers in pharmacology · 2025Review
- Nanomedicine in glaucoma treatment; Current challenges and future perspectives.Materials today. Bio · 2024Review
- Review: Neuroprotective Nanocarriers in Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Application of Silicone in Ophthalmology: A Review.Materials (Basel, Switzerland) · 2024Review
- Neuroprosthetic contact lens enabled sensorimotor system for point-of-care monitoring and feedback of intraocular pressure.Nature communications · 2024Article
- Injectable drug-loaded thermosensitive hydrogel delivery system for protecting retina ganglion cells in traumatic optic neuropathy.Regenerative biomaterials · 2024Article
- Polymer-Based Self-Assembled Drug Delivery Systems for Glaucoma Treatment: Design Strategies and Recent Advances.Polymers · 2023Review
- Sustained release of brimonidine from polydimethylsiloxane-coating silicone rubber implant to reduce intraocular pressure in glaucoma.Regenerative biomaterials · 2023Article
- Article
- Advancing Glaucoma Treatment through Materials Science: A Bibliometric Analysis.Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Glaucoma is a leading cause of irreversible visual impairment and blindness, affecting over 76.0 million people worldwide in 2020, with a predicted increase to 111.8 million by 2040. Hypotensive eye drops remain the gold standard for glaucoma treatment, while inadequate patient adherence to medication regimens and poor bioavailability of drugs to target tissues are major obstacles to effective treatment outcomes. Nano/micro-pharmaceuticals, with diverse spectra and abilities, may represent a hope of removing these obstacles. This review describes a set of intraocular nano/micro drug delivery systems involved in glaucoma treatment. Particularly, it investigates the structures, properties, and preclinical evidence supporting the use of these systems in glaucoma, followed by discussing the route of administration, the design of systems, and factors affecting in vivo performance. Finally, it concludes by highlighting the emerging notion as an attractive approach to address the unmet needs for managing glaucoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.